Evidence map›Paper›PMID 25315888›Full record

ArticleTissue engineering. Part A2015

Abluminal stimulation of sphingosine 1-phosphate receptors 1 and 3 promotes and stabilizes endothelial sprout formation.

Anusuya Das, Steven M Lenz, Anthony O Awojoodu, Edward A Botchwey

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering. Part A, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Signal Transduction and Gene Regulation in the Endothelium.Cold Spring Harbor perspectives in medicine · 2023
    Review
  4. Loss of sphingosine 1-phosphate receptor 3 gene function impairs injury-induced stromal angiogenesis in mouse cornea.Laboratory investigation; a journal of technical methods and pathology · 2021
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Anusuya Das1 Department of Orthopaedic Surgery, University of Virginia , Charlottesville, Virginia.
Steven M Lenz
Anthony O Awojoodu
Edward A Botchwey
University of Virginia · US

Funding

Phospholipid Growth Factors for Therapeutic Arteriogenesis and Tissue EngineeringR01AR056445 · NIAMS · UNIVERSITY OF VIRGINIA · PI BOTCHWEY, EDWARD A. · 2009 to 2014
$1.8M
Therapeutic S1P Drug Targets for Cranial Bone RepairR01DE019935 · NIDCR · UNIVERSITY OF VIRGINIA · PI BOTCHWEY, EDWARD A. · 2009 to 2013
$1.8M
NIAMS NIH HHS R01 AR056445NIDCR NIH HHS R01 DE019935
6 · The paper itself

Abstract

Local delivery of lipid mediators has become a promising new approach for therapeutic angiogenesis and regenerative medicine. In this study, we investigated how gradient stimulation (either abluminal/distal or luminal/proximal) of engineered microvessels with sphingosine 1-phosphate (S1P) receptor-subtype-targeted molecules affects endothelial sprout growth using a microfluidic device. Our studies show that distal stimulation of microvessels with FTY720, an S1P1/3 selective agonist, promotes both arterial and venular sprout growth, whereas proximal stimulation does not. Using novel pharmacological antagonists of S1P receptor subtypes, we further show that S1P3 functionality is necessary for VEGF-induced sprouting, and confirmed these findings ex vivo using a murine aortic ring assay from S1P3-deficient mice. S1P3 agonist stimulation enhanced vascular stability in both cell types via upregulation of the interendothelial junction protein VE-cadherin. Lastly, S1P3 activation under flow promoted endothelial sprouting and branching while decreasing migratory cell fate in the microfluidic device. We used an in vivo murine dorsal skinfold window chamber model to confirm S1P3's role in neovascular branching. Together, these data suggest that a distal transendothelial gradient of S1P1/3-targeted drugs is an effective technique for both enhancing and stabilizing capillary morphogenesis in angiogenic applications.

Indexed as

Neovascularization, PhysiologicAnimalsAntigens, CDAortaCadherin 5CadherinsCell MovementDiffusionEndothelial CellsHumansHuman Umbilical Vein Endothelial CellsIn Vitro TechniquesMaleMice, Inbred C57BLReceptors, LysosphingolipidVascular Endothelial Growth Factor AAntigens, CDCadherin 5CadherinsReceptors, LysosphingolipidVascular Endothelial Growth Factor A

Identifiers

PMID25315888
PMCPMC4293135
OpenAlexW1920103403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.